| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8452661 | Experimental Hematology | 2018 | 22 Pages |
Abstract
- Lusutrombopag is a novel, orally active, small-molecule thrombopoietin (TPO) receptor agonist.
- Lusutrombopag acts specifically acts on human TPO receptors.
- Lusutrombopag exhibited differentiation and proliferation of megakaryocytic cells.
- A novel knock-in mouse was created by replacing mMpl with human-mouse chimera Mpl.
- Oral dosing of lusutrombopag significantly increased platelets in TPOR-Ki/Shi mice.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hiroshi Yoshida, Hajime Yamada, Wataru Nogami, Keiji Dohi, Tomomi Kurino-Yamada, Koji Sugiyama, Koji Takahashi, Yoshinari Gahara, Motoji Kitaura, Minoru Hasegawa, Itsuki Oshima, Kenji Kuwabara,